Form 8-K

8-K — Turn Therapeutics Inc.

Accession: 0001213900-26-075757

Filed: 2026-07-07

Period: 2026-07-07

CIK: 0002023016

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — ea0297061-8k_turn.htm (Primary)

EX-99.1 — PRESS RELEASE, DATED JULY 7. 2026 (ea029706101ex99-1.htm)

EX-99.2 — INVESTOR PRESENTATION, DATED JULY 7, 2026 (ea029706101ex99-2.htm)

GRAPHIC (ea029706101_ex99-1img1.jpg)

GRAPHIC (ea029706101_ex99-2img1.jpg)

GRAPHIC (ea029706101_ex99-2img2.jpg)

GRAPHIC (ea029706101_ex99-2img3.jpg)

GRAPHIC (ea029706101_ex99-2img4.jpg)

GRAPHIC (ea029706101_ex99-2img5.jpg)

GRAPHIC (ea029706101_ex99-2img6.jpg)

GRAPHIC (ea029706101_ex99-2img7.jpg)

GRAPHIC (ea029706101_ex99-2img8.jpg)

GRAPHIC (ea029706101_ex99-2img9.jpg)

GRAPHIC (ea029706101_ex99-2img10.jpg)

GRAPHIC (ea029706101_ex99-2img11.jpg)

GRAPHIC (ea029706101_ex99-2img12.jpg)

GRAPHIC (ea029706101_ex99-2img13.jpg)

GRAPHIC (ea029706101_ex99-2img14.jpg)

GRAPHIC (ea029706101_ex99-2img15.jpg)

GRAPHIC (ea029706101_ex99-2img16.jpg)

GRAPHIC (ea029706101_ex99-2img17.jpg)

GRAPHIC (ea029706101_ex99-2img18.jpg)

GRAPHIC (ea029706101_ex99-2img19.jpg)

GRAPHIC (ea029706101_ex99-2img20.jpg)

GRAPHIC (ea029706101_ex99-2img21.jpg)

GRAPHIC (ea029706101_ex99-2img22.jpg)

GRAPHIC (ea029706101_ex99-2img23.jpg)

GRAPHIC (ea029706101_ex99-2img24.jpg)

GRAPHIC (ea029706101_ex99-2img25.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0297061-8k_turn.htm · Sequence: 1

false

0002023016

2026-07-07

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant

to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

July 7, 2026

TURN THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

Delaware

001-42875

32-0456090

(State or other jurisdiction of

incorporation)

(Commission File Number)

(IRS Employer

Identification Number)

250 N. Westlake Blvd., Westlake Village, California

91362

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including

area code: (818) 564-4011

N/A

(Former name or former address, if changed since

last report)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol

Name

of Each Exchange on Which Registered

Common Stock, par value $0.0001 per share

TTRX

The Nasdaq Stock Market

LLC

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the

Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On July 7, 2026, Turn Therapeutics

Inc. issued a press release (the “Press Release”). A copy of the Press Release is furnished as Exhibit 99.1 to this Current

Report on Form 8-K.

On July 7, 2026, Turn Therapeutics

Inc. released an updated investor presentation (the “Investor Presentation”). A copy of the Investor Presentation is furnished

as Exhibit 99.2 to this Current Report on Form 8-K.

The information in Item 7.01

of this Current Report on Form 8-K, including the Press Release furnished as Exhibit 99.1, and the Investor Presentation furnished as

Exhibit 99.2 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended

(the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference

in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in

such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

99.1

Press Release, dated July 7. 2026

99.2

Investor Presentation, dated July 7, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements

of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto

duly authorized.

TURN THERAPEUTICS INC.

Date: July 7, 2026

By:

/s/ Bradley Burnam

Name:

Bradley Burnam

Title:

Chief Executive Officer

EX-99.1 — PRESS RELEASE, DATED JULY 7. 2026

EX-99.1

Filename: ea029706101ex99-1.htm · Sequence: 2

Exhibit 99.1

Turn Therapeutics Announces Final Stage 2 Design

and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis

Clinically meaningful efficacy observed across

a broader spectrum of atopic dermatitis supports expansion of the ongoing Phase 2 program to prospectively evaluate patients across the

full range of disease severity as defined by the Eczema Area and Severity Index (EASI)

Comprehensive interim review identifies optimal

patient population, endpoint strategy, disease stratification, and statistical methodology for final Stage 2 design of the Company's ongoing

adaptive Phase 2 trial in atopic dermatitis

Final Stage 2 design will employ the FDA-recognized

Hochberg multiple testing procedure, allowing statistical significance to be established across multiple efficacy endpoints rather than

a single primary endpoint

Company to host investor webcast today at 4:30

p.m. Eastern Time

WESTLAKE VILLAGE, Calif., July 7, 2026 —

Turn Therapeutics, Inc. (NASDAQ: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory

skin diseases, today announced the completion of a comprehensive interim analysis of its ongoing adaptive Phase 2 clinical trial evaluating

GX-03 for the treatment of atopic dermatitis.

The multi-week review resulted in the final Stage

2 study design, incorporating data-driven refinements to patient selection, disease stratification, endpoint evaluation, and statistical

methodology. Importantly, the review identified clinically meaningful efficacy across a broader spectrum of atopic dermatitis severity

than originally anticipated, enabling expansion of the ongoing Phase 2 program to prospectively evaluate patients across the full spectrum

of baseline disease severity as measured by the Eczema Area and Severity Index (EASI).

Following the Company's previously disclosed preliminary

interim review of the first 50 completed subjects and under the oversight of the Independent Data Monitoring Committee, Turn Therapeutics

initiated a comprehensive planned interim analysis led by Bruce Stouch, Ph.D., the study's lead biostatistician, together with Dr. Stephen

Hahn, Executive Clinical and Regulatory Lead for Turn Therapeutics and former Commissioner of the U.S. Food and Drug Administration. The

multi-week review comprehensively evaluated treatment-response patterns, baseline disease characteristics, efficacy across prespecified

and exploratory endpoints, and clinically relevant patient characteristics to maximize the scientific value of the Stage 1 dataset and

optimize the final Stage 2 study design, which is intended to serve as the primary efficacy phase supporting future regulatory development.

Enrollment continued uninterrupted throughout the review under the adaptive trial design, and all patients enrolled during this period

remain blinded and will be prospectively evaluated under the final Stage 2 study design.

“The purpose of a staged, adaptive clinical

trial is to learn from the first stage to strengthen the second,” said Bradley Burnam, Chief Executive Officer of Turn Therapeutics. “GX-03

demonstrated meaningful activity across a wider spectrum of atopic dermatitis severity than we originally anticipated. We believe the

optimized Stage 2 design strengthens the current study while generating data that could support broader development and future labeling

opportunities for GX-03.”

The comprehensive interim review confirmed preliminary

observations that Week 4 provided the earliest and clearest treatment separation between GX-03 and vehicle, supporting inclusion of Week

4 efficacy endpoints in the final Stage 2 design and highlighting the potential for a rapidly acting topical therapy across the atopic

dermatitis severity spectrum. The analyses also identified baseline pruritus severity as a potential biomarker of treatment response,

supporting prospective enrichment of the Stage 2 population. In addition, GX-03 demonstrated clinically meaningful efficacy in patients

with baseline Eczema Area and Severity Index (EASI) scores of 1.1 to 7.0, a population generally considered to have mild-to-moderate disease

according to the EASI scale, expanding the range of disease severity prospectively evaluated in Stage 2 beyond what was originally anticipated.

Collectively, these findings supported a final Stage 2 design evaluating one unified patient population across the full baseline EASI

spectrum using multiple efficacy endpoints.

Expansion of the Ongoing Phase 2 Program

One of the most significant findings from the

comprehensive interim review was the identification of treatment activity in patients with baseline EASI scores of 1.1 to 7.0. While all

Stage 1 participants had moderate-to-severe lesions according to the Investigator's Global Assessment (IGA), enrollment included patients

across a broad range of baseline EASI scores, reflecting a wide spectrum of total inflammatory burden. The observed efficacy in patients

with EASI scores of 1.1 to 7.0 identified a potential treatment opportunity in the EASI-defined mild-to-moderate atopic dermatitis population,

which is commonly managed with topical therapies. Within this subgroup, GX-03 demonstrated improvements in Week 4 vIGA-AD Success together

with complete disease clearance at both Week 4 and Week 8 compared with vehicle. Based on these findings, the final Stage 2 design continues

to evaluate patients with greater inflammatory burden while prospectively expanding enrollment to include patients across the full baseline

EASI spectrum (EASI ≥1.1).

EASI 1.1-7.0 Subgroup

from Interim Analysis

Endpoint

GX-03

(n=14)

Vehicle

(n=18)

Treatment Difference

Week 4 vIGA-AD Success

71.4% (10/14 )

33.3% (6/18 )

+38.1 %

Week 4 EASI-100

28.6% (4/14 )

5.6% (1/18 )

+23.0 %

Week 8 EASI-100

35.7% (5/14 )

11.1% (2/18 )

+24.6 %

Completed interim analysis patients with EASI = 1.1 – 7.0 demonstrated

treatment responses during Stage 1

Final Stage 2 Study Design

The final Stage 2 population will include approximately

120-135 patients prospectively enrolled across the full baseline Eczema Area and Severity Index (EASI) spectrum (EASI 1.1-7.0, 7.1-15.9

and ≥16). Subjects will be stratified by baseline EASI category, with 1:1 randomization maintained within each stratum. The study will

evaluate four prespecified efficacy endpoints representing progressively deeper levels of clinical response using the FDA-recognized Hochberg

multiple testing procedure, which preserves rigorous control of Type I error while allowing statistical significance to be established

across multiple clinically meaningful efficacy endpoints rather than a single primary endpoint.

Key Elements of the Final Stage 2 Design

● Approximately 120-135 patients,

including those enrolled since the interim analysis, prospectively stratified into three baseline EASI severity groups (1.1-7.0, 7.1-15.9

and ≥16), with 1:1 randomization maintained within each stratum. Every enrolled patient will contribute to a single, unified efficacy

analysis that prospectively evaluates GX-03 across a broader spectrum of atopic dermatitis than originally anticipated.

● Prospective evaluation of four prespecified efficacy endpoints

using the Hochberg multiple testing procedure:

○ Week 4 vIGA-AD Success

○ Week 4 EASI-75

○ Week 8 EASI-90

○ Week 8 EASI-100

● Continued uninterrupted enrollment throughout

the comprehensive interim review, with patients enrolled during this period remaining blinded and incorporated directly into the final

Stage 2 efficacy population.

Interim Analysis Subgroup

Representative of Final Stage 2 Design

Endpoint

GX-03

(n=13)

Vehicle

(n=12)

Treatment Difference

Week 4 vIGA-AD Success

61.5% (8/13 )

8.3% (1/12 )

+53.2 %

Week 4 EASI-75

69.2% (9/13 )

25.0% (3/12 )

+44.2 %

Week 8 EASI-90

53.8% (7/13 )

16.7% (2/12 )

+37.1 %

Week 8 EASI-100

46.2% (6/13 )

8.3% (1/12 )

+37.9 %

Completed interim analysis patients representative of the final Stage 2 design criteria

(EASI ≥ 1.1 and PP-NRS ≥ 7) demonstrated treatment responses during Stage 1, providing the scientific rationale for the optimized

enrollment strategy

The figure above illustrates the scientific basis

for the Stage 2 study design. Applying the final Stage 2 enrollment criteria to the completed interim analysis population demonstrated

notable statistical separation from vehicle across all four prespecified efficacy endpoints.

Consistent with previous reports, no treatment-related

serious adverse events have been observed in either treatment group, and no treatment-related tolerability issues or study discontinuations

have been reported. GX-03 continues to demonstrate a favorable safety and tolerability profile. Enrollment has continued uninterrupted

throughout the comprehensive interim review, and all patients enrolled during this period remain blinded and will be incorporated into

the final Stage 2 analyses. Enrollment will continue under the final Stage 2 protocol, and Turn Therapeutics anticipates completing enrollment

during the fourth quarter of 2026. The Company remains sufficiently capitalized to support completion of the study and planned operations

through the third quarter of 2027.

Conference Call

Turn Therapeutics will host a webcast today, July

7, at 4:30 p.m. Eastern Time to discuss the comprehensive interim analysis, expansion of the ongoing Phase 2 program, and the detailed

Stage 2 study design for GX-03.

Bradley Burnam, Chief Executive Officer, and Dr.

Stephen Hahn, Executive Clinical and Regulatory Lead, will present.

To access the live webcast, please register at

https://edge.media-server.com/mmc/p/jix773zk. A replay of the webcast, along

with accompanying presentation materials, will be available in the Investor Relations section of the Company's website at https://ir.turntherapeutics.com

following the conclusion of the call.

About Turn Therapeutics

Turn Therapeutics is a clinical-stage biotechnology

company focused on developing targeted, localized therapies for inflammatory and infectious skin diseases. GX-03 is Turn Therapeutics'

lead investigational topical candidate being developed as a targeted, non-systemic treatment for atopic dermatitis, designed to deliver

biologic-level efficacy without the trade-offs of injectable administration or systemic immunosuppression.

Forward-Looking Statements

This press release contains forward-looking statements

within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact,

contained in this press release are forward-looking statements, including statements regarding clinical development plans, optimization

of enrollment criteria and endpoints, interpretation of interim clinical observations, expected trial timing, regulatory interactions,

and the therapeutic potential of GX-03. Forward-looking statements contained in this press release may be identified by the use of words

such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,”

“intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,”

“project,” “suggest,” “target,” “aim,” “should,” “will,” “would,”

or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking

statements are based on Turn’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult

to predict, including risks related to the success of development programs, the availability of additional financing, and the Company’s

ability to execute its strategic plan. Further, certain forward-looking statements are based on assumptions as to future events that may

not prove to be accurate. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed

in these forward-looking statements, as well as risks relating to the business of Turn Therapeutics in general, see the risk disclosures

in the Company’s filings with the SEC. All such forward-looking statements speak only as of the date they are made, and Turn undertakes

no obligation to update or revise these statements, whether as a result of new information, future events, or otherwise.

Investor Relations / Media Contact

Sasha Damouni

The Damouni Group

Sasha@damounigroup.com

EX-99.2 — INVESTOR PRESENTATION, DATED JULY 7, 2026

EX-99.2

Filename: ea029706101ex99-2.htm · Sequence: 3

Exhibit 99.2

GX-03: Phase 2, Stage 2 Overview & Additional Interim Analysis Insights Investor Webcast Presentation July 7, 2026

2 Disclaimers & Safe Harbour Except for historical information set forth herein, the matters set forth in this presentation contain forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue,” the negative of these terms and other comparable terminology. We cannot guarantee future results, level of activity, performance or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements. We are under no duty to update any of these forward-looking statements after the date of this presentation to conform our prior statements to actual results or revised expectations. These statements are based upon the current beliefs and expectations of Turn Therapeutics’ management and are subject to significant risks and uncertainties. By their nature, forward-looking statements involve risks and uncertainties because they depend on circumstances that may or may not occur in the future. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially. Risks include: industry competition; economic factors; regulatory challenges; uncertainties in clinical development and obtaining regulatory approvals; no guarantees that pipeline products will prove commercially successful; reliance on third-party partnerships and manufacturers; dependence on patent protections for PermaFusion®; and ability to access adequate capital. Although these statements are based on assumptions we believe are reasonable, we caution that forward-looking statements are not guarantees of future performance and you should not place undue reliance on them. Turn Therapeutics undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors can be found in the company’s SEC filings available at www.sec.gov. This presentation includes market and industry data and forecasts that the Company has derived from independent consultant reports, publicly available information, various industry publications, other published industry sources, and its internal data and estimates. Independent consultant reports, industry publications and other published industry sources generally indicate that the information contained therein was obtained from sources believed to be reliable. Although the Company believes that these third-party sources are reliable, it does not guarantee the accuracy or completeness of this information, and the Company has not independently verified this information. The Company’s internal data and estimates are based upon information obtained from trade and business organizations and other contacts in the markets in which the Company operates and management’s understanding of industry conditions. Although the Company believes that such information is reliable, it has not had this information verified by any independent sources. In addition, the information contained in this presentation is as of the date hereof (except where otherwise indicated), and the Company has no obligation to update such information, including in the event that such information becomes inaccurate or if estimates change. Subsequent materials may be provided by or on behalf of the Company in its discretion and such information may supplement, modify or supersede the information in these materials. Neither the Company, nor any of its respective affiliates, advisors or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss or damage howsoever arising from any use of these materials or their contents or otherwise arising in connection with these materials. This presentation may contain trademarks, service marks, trade names and copyrights of other companies, which are the property of their respective owners. Solely for convenience, some of the trademarks, service marks, trade names and copyrights referred to in this presentation may be listed without the TM, SM or symbols, but the Company will assert, to the fullest extent under applicable law, the rights of the applicable owners, if any, to these trademarks, service marks, trade names and copyrights.

3 Bradley Burnam Chief Executive Officer

4 Why Do a Staged Adaptive Study? 4 Learn from Stage 1 findings to design Stage 2 for clinical success Core Purpose of an Adaptive Design Study Strategic Advantage of Adaptive Trials ▪Higher Probability of Success: Refinement of Stage 2 from learnings of Stage 1 increases the probability of success ▪Smarter Resource Use: Endpoints, timepoints and target patient population can be optimized with real data ▪Built-in Flexibility: Study adapts as evidence accumulates, rather than locking in decisions made before drug and human interaction

How is Atopic Dermatitis Severity Measured? 5 Lesion Severity vs Inflammatory Burden Lesion Severity Measured through vIGA-AD Inflammatory Burden Measured through EASI vIGA = 4 EASI≈1.1 vIGA = 4 EASI ≈ 17 ▪ Validated Investigator Global Assessment (vIGA-AD): A 5 point scale (0-4) rating overall disease severity based on the worst lesion characteristics – erythema, papulation, and lichenification. ▪ Eczema Area Severity Index (EASI): A weighted score (0-72) that accounts for the extent (% body surface area) and intensity of inflammation across 4 body regions. ▪ Key Difference: vIGA reflects the severity of the single worst area; EASI captures total inflammatory burden across the whole body.

6 Moderate-Severe AD: Assessing for Stage 2 EASI Enrichment IGA 3/4 & Baseline EASI ≥ 10 6 Baseline Characteristics GX-03 n=9 Vehicle n=4 Mean EASI (SD) 22.1 (10.8) 14.8 (3.51) Mean vIGA (SD) 3.44 (0.49) 3.25 (0.43) Endpoint GX-03 (n=9) Vehicle (n=4) Treatment Difference Week 4 vIGA-AD Success vIGA of 0/1 with ≥ 2 grade improvement 55.6% (5/9) 25.0% (1/4) Δ 30.6% Week 4 EASI-75 88.9% (8/9) 50.0% (2/4) Δ 38.9% Week 8 EASI-90 77.8% (7/9) 50.0% (2/4) Δ 27.8% Week 8 EASI-100 44.4% (4/9) 50.0% (2/4) Δ -5.6% Baseline characteristics favor Vehicle

7 Interim Analysis - EASI 1.1 – 7 Subgroup Presents as Meaningful on Key Disease Clearance Endpoints 7 Endpoints GX-03 (n=14) Vehicle (n=18) Treatment Difference Week 4 vIGA-AD Success vIGA of 0/1 with ≥ 2 grade improvement 71.4% (10/14) 33.3% (6/18) Δ 38.1% Week 4 EASI-100 28.6% (4/14) 5.6% (1/18) Δ 23.1% Week 8 EASI-100 35.7% (5/14) 11.1% (2/18) Δ 24.6% Baseline Characteristics GX-03 n=14 Vehicle n=18 Mean EASI (SD) 3.59 (1.71) 3.99 (1.70) Mean vIGA (SD) 3 (0.69) 3 (0.79) Balanced Population Baseline disease severity was well balanced between treatment groups, supporting interpretation of the observed treatment differences.

Pruritus as Potential Predictive Biomarker for AD Success 8 Week 4 vIGA-AD Success (vIGA of 0/1 with ≥ 2 grade improvement) Week 4 EASI-75 (≥75% Improvement from Baseline) Week 8 EASI-90 (≥90% Improvement from Baseline) Week 8 EASI-100 (Complete Clearance) PP-NRS ≥ 5 N=40 (80% of Stage 1completers) GX-03: n=21 Vehicle: n=19 PP-NRS ≥ 6 N=35 (70% of Stage 1 completers) GX-03: n=18 Vehicle: n=17 PP-NRS ≥ 7 N=25 (50% of Stage 1 completers) GX-03: n=13 Vehicle: n=12 GX-03 Vehicle Higher baseline pruritus severity is consistently associated with stronger responses across all four efficacy endpoints Enriching for PP-NRS ≥ 7 increases event rates and maximizes Stage 2 efficiency Why Enrichment Improves Stage 2 Efficiency • Greater treatment separation vs. vehicle observed at every endpoint • Higher event rates requires smaller sample size • More efficient path to achieving statistically significant results GX-03 Vehicle GX-03 Vehicle 61.9% 72.2% 61.5% 21.1% 17.7% 8.3% GX-03 Vehicle GX-03 Vehicle GX-03 Vehicle 71.4% 77.8% 69.2% 47.4% 47.1% 25.0% GX-03 Vehicle GX-03 Vehicle GX-03 Vehicle 42.9% 50.0% 53.8% 31.6% 29.4% 16.7% GX-03 Vehicle GX-03 Vehicle GX-03 Vehicle 38.1% 44.4% 46.2% 15.8% 17.7% 8.3% Stage 2 Representative Population Δ 40.8% Δ 54.5% Δ53.2% Δ 44.2% Δ 30.7% Δ 24.0% Δ 11.3% Δ 20.6% Δ 37.1% Δ 37.9% Δ 26.7% Δ 22.3%

Stage 2 Design – Prospective Stratification by EASI 9 2. Baseline EASI Stratified by baseline EASI score ▪ Separate strata(s) prevents imbalanced disease severity among GX-03 and Vehicle ▪ Stratified patient population represents full disease spectrum and EASI≥16 groups represent potential biological therapy candidates ▪ Intentional weighting among disease groups to generate robust treatment separation 1. Baseline PP-NRS Baseline ≥ 7 – Mandatory Inclusion Criteria 3. Baseline vIGA-AD Baseline ≥ 3 – Mandatory Inclusion Criteria Enrollment Criteria & Stratification N= ~60 Baseline EASI 1.1-7 1:1 Randomized N= ~60 Baseline EASI 7.1-15.9 1:1 Randomized N= ~15 Baseline EASI ≥ 16 1:1 Randomized Three Targeted Enrollment Groups Stratified by Baseline EASI Balanced by Biased Coin Randomization Enrollment Continued during Stage 1 Analysis and Stage 2 Optimization

Stage 2 Design – Selected Endpoints 10 Endpoints and timepoints optimized from observed separation and effect in Stage 1 Selected Endpoints Family To be evaluated using Hochberg Method ▪ Week 4 – vIGA-AD Success (vIGA of 0/1 with ≥ 2 grade improvement) ▪ Week 4 – EASI-75 ▪ Week 8 – EASI-90 ▪ Week 8 – EASI-100 Primary Statistical Analysis The entire enriched efficacy population will be evaluated using a single prespecified Hochberg multiple-testing method across the four clinically meaningful endpoints. Stronger signals emerged at Week 4 from Stage 1 with responses deepening through Week 8 Hochberg Method Characteristics: - One primary population - One analysis set - No alpha (α) allocation - Full alpha (α) directed to a single multiplicity- controlled analysis

11 Stage 2 Design – Summary Design: • Double-blind • 1:1 Randomized w/ Prospective 1:1 Stratification • Vehicle Controlled • BID Topical • Week 4 and Week 8 Endpoints • IDMC Governed Adaptive Design 11 Stage 2 Optimized Design Selected Endpoints: • Week 4 – vIGA-AD of 0/1 with ≥ 2 grade improvement • Week 4 – EASI-75 • Week 8 – EASI-90 • Week 8 – EASI-100 Endpoints will be evaluated using a single prespecified Hochberg multiple-testing method across the four endpoints. Population: • N = ~ 120-135 • EASI ≥ 1.1, IGA ≥ 3 and PP-NRS ≥ 7 • Age: 18 – 80 • No concomitant therapy 2026 2027 June 2026 Stage 1 Complete Q4 2026 Topline Results Expected N = 50 Adaptive design Ongoing Stage 2 Enrollment

12 Stage 2 Design - Representative Subgroup from Interim Analysis Baseline EASI ≥ 1.1 and Baseline PP-NRS ≥ 7 12 Endpoint GX-03 (n=13) Vehicle (n=12) Treatment Difference Week 4 vIGA-AD Success vIGA of 0/1 with ≥ 2 grade improvement 61.5% (8/13) 8.3% (1/12) Δ 53.2% Week 4 EASI-75 69.2% (9/13) 25.0% (3/12) Δ 44.2% Week 8 EASI-90 53.8% (7/13) 16.7% (2/12) Δ 37.1% Week 8 EASI-100 46.2% (6/13) 8.3% (1/12) Δ 37.9% Baseline Characteristics GX-03 n=13 Vehicle n=12 Mean EASI (SD) 12.1 (13.3) 7.2 (5.7) Mean vIGA (SD) 3.15 (0.36) 3.08 (0.49) Baseline characteristics favor Vehicle

13 Dr. Stephen Hahn Clinical and Regulatory Lead

14 1. The National Eczema Association (NEA) 2. Largest by patient population, fastest based on projected market size (EvaluatePharma) 16.5M US adult patients suffer from AD 6.6M adult patients in moderate-severe category 1 High Unmet Needs ▪Safe therapies ▪Non-systemic therapies ▪Rapid Action ▪Needle-free options Atopic Dermatitis Prevalence 14 9.6M children under age 18 suffer from AD 3.2M children under age 18 suffer from mod-severe AD 1 AD is the largest and fastest growing I&I market 2 in the U.S. Adult Patient Population (≥18 years) Children Patient Population ( <18 years)

15 Stage 1 - Safety Summary 15 *Subject reported a mild warming sensation that was described as pleasant. **Subject reported a common cold which was determined by PI to not be treatment related. GX-03 Vehicle N = 27 N = 23 Subjects with AE, n 1* 1** Severe (Grade ≥ 2) 0 0 Serious AEs 0 0 AEs leading to study drug discontinuation 0 0

16 GX-03 - Clinical & Regulatory Timeline in AD 16 2026 2027 June 2026 Stage 1 Complete Q4 2026 Topline Results Expected N = 50 Adaptive design Q4 2026 Type-B Meeting Expected 1H 2027 Phase 3 Initiation* *Subject to successful completion of each phase and capital availability

17 GX-03 Market Opportunity 1. Subject to successful completion of each phase and capital availability. Why GX-03 For Atopic Dermatitis 02 03 PDE4 / AhR Lower Studied Efficacy vs. Orals & Injectables Side effects risk Biologics Systemic burden Immunosuppression Extended loading period 01 Topical Steroids Persistent use can cause fat atrophy and necrosis of the skin Dose response reduction may occur with consistent use GX-03 has the potential to serve as a safer, faster alternative to systemic therapies¹

Investors@turntherapeutics.com 250 N. Westlake Blvd, #210 Westlake Village, CA 91362 Thank You!

19 Appendix

20 Stage 2 Representative Subgroup from Interim Analysis Baseline EASI ≥ 1.1 and Baseline PP-NRS ≥ 7 20 GX-03 Vehicle n=13 n=12 8.3% 61.5% Δ 53.2% Week 4 vIGA Success Week 8 EASI-90 Week 8 EASI-100 Week 4 EASI-75 GX-03 Vehicle n=13 n=12 25.0% 69.2% Δ 44.2% GX-03 Vehicle n=13 n=12 16.7% 53.8% Δ 37.1% GX-03 Vehicle n=13 n=12 8.3% 46.2% Δ37.9%

21 21 30.40% 32.10% 45.90% 52.60% 27.60% Zoryve Week 4 Eucrisa Week 4 Vtama Week 8 Opzelura Week 8 Anzupgo Week 8 FDA Approved Topical AD Drugs 25% 50% 75% IGA 0/1 with ≥ 2 Grade Improvement (%) SOURCE: Zoryve (roflumilast 0.15% cream QD; average of Phase 3 INTEGUMENT-1 & INTEGUMENT-2; vIGA-AD success at Week 4.. Eucrisa (crisaborole 2% ointment BID; average of Phase 3 AD-301 & AD-302; ISGA success at Day 29 (~Week 4). Vtama (tapinarof 1% cream QD; average of Phase 3 ADORING 1 & ADORING 2; vIGA-AD success at Week 8. Opzelura (ruxolitinib 1.5% cream BID; average of Phase 3 TRuE- AD1 & TRuE-AD2; IGA-TS at Week 8. Anzupgo (delgocitinib 2% cream; average of Phase 3 DELTA 1 & DELTA 2 for chronic hand eczema; IGA-CHE treatment success. Mild-Mod AD Mild-Mod AD Mod-Severe AD Mild-Mod AD Mod-Severe CHE IGA Success NOTE: For illustrative purposes only. Efficacy data are derived from different clinical trials conducted at different times, with differences in trial design and patient populations. As a result, cross-trial comparisons cannot be made, and no head-to-head clinical trials have been conducted. Statistical treatment of missing data varies across studies shown.

22 22 42.60% 57.45% 62.00% Zoryve Week 4 Vtama Week 8 Opzelura Week 8 FDA Approved Topical AD Drugs 25% 50% 75% EASI-75 (% patients) SOURCE: Zoryve (roflumilast 0.15% cream QD; average of Phase 3 INTEGUMENT-1 & INTEGUMENT-2; EASI-75 at Week 4). Vtama (tapinarof 1% cream QD; average of Phase 3 ADORING 1 & ADORING 2; EASI- 75 at Week 8). Opzelura (ruxolitinib 1.5% cream BID; average of Phase 3 TRuE-AD1 & TRuE-AD2; EASI-75 at Week 8). Mild-Mod AD Mod-Severe AD Mild-Mod AD EASI-75 NOTE: For illustrative purposes only. Efficacy data are derived from different clinical trials conducted at different times, with differences in trial design and patient populations. As a result, cross-trial comparisons cannot be made, and no head-to-head clinical trials have been conducted. Statistical treatment of missing data varies across studies shown.

23 23 46.00% 34.60% 37.00% 36.70% 19.00% Zumilokibart (mid-dose) Week 16 Dupixent Week 16 Ebglyss Week 16 Nemluvio Week 16 Adbry Week 16 FDA Approved and Clinical Stage Biologics in AD 25% 50% IGA 0/1 with ≥ 2 Grade Improvement (%) SOURCE: Zumilokibart (mid-dose from APEX Phase 2 Part B 16-weeks Results). DUPIXENT (average of Ph3 SOLO-1&2 and Ph2b; 300 mg Q2W regimen; non-responder imputation for missing values). EBGLYSS (average of Ph3 ADVOCATE-1&2 (non-responder imputation for missing values) and Ph2b (sensitivity analysis 3: NRI for rescue medication use and LOCF for other missing values); 250mg Q2W regimen). NEMLUVIO+TCS (average of Ph3 ARCADIA1 30 mg Q4W regimen; non-responder imputation for missing data). ADBRY (average of Ph3 ECZTRA1 300 mg Q2W regimen; non-responder imputation for missing values). Clinical Stage IGA Success NOTE: For illustrative purposes only. Efficacy data are derived from different clinical trials conducted at different times, with differences in trial design and patient populations. As a result, cross-trial comparisons cannot be made, and no head-to-head clinical trials have been conducted. Statistical treatment of missing data varies across studies shown. Zumilokibart assessed vIGA 0/1 while DUPIXENT, EBGLYSS, NEMLUVIO+TCS, and ADBRY assessed IGA 0/1

24 24 65.90% 49.50% 53.00% 42.80% 29.10% Zumilokibart (mid-dose) Week 16 Dupixent Week 16 Ebglyss Week 16 Nemluvio Week 16 Adbry Week 16 25% 50% 75% EASI-75 (% patients) SOURCE: Zumilokibart (mid-dose from APEX Phase 2 Part B 16-weeks Results). DUPIXENT (average of Ph3 SOLO-1&2 and Ph2b; 300 mg Q2W regimen; non-responder imputation for missing values). EBGLYSS (average of Ph3 ADVOCATE-1&2 (non-responder imputation for missing values) and Ph2b (sensitivity analysis 3: NRI for rescue medication use and LOCF for other missing values); 250mg Q2W regimen). NEMLUVIO+TCS (average of Ph3 ARCADIA1 30 mg Q4W regimen; non-responder imputation for missing data). ADBRY (average of Ph3 ECZTRA1 300 mg Q2W regimen; non-responder imputation for missing values). Clinical Stage EASI-75 NOTE: For illustrative purposes only. Efficacy data are derived from different clinical trials conducted at different times, with differences in trial design and patient populations. As a result, cross-trial comparisons cannot be made, and no head-to-head clinical trials have been conducted. Statistical treatment of missing data varies across studies shown. FDA Approved and Clinical Stage Biologics in AD

25 25 47.40% 31.80% 34.50% 25.80% 16.40% Zumilokibart (mid-dose) Week 16 Dupixent Week 16 Ebglyss Week 16 Nemluvio Week 16 Adbry Week 16 25% 50% EASI-90 (% patients) SOURCE: Zumilokibart (mid-dose from APEX Phase 2 Part B 16-weeks Results). DUPIXENT (average of Ph3 SOLO-1&2 and Ph2b; 300 mg Q2W regimen; non-responder imputation for missing values). EBGLYSS (average of Ph3 ADVOCATE-1&2 (non-responder imputation for missing values) and Ph2b (sensitivity analysis 3: NRI for rescue medication use and LOCF for other missing values); 250mg Q2W regimen). NEMLUVIO+TCS (average of Ph3 ARCADIA1 30 mg Q4W regimen; non-responder imputation for missing data). ADBRY (average of Ph3 ECZTRA1 300 mg Q2W regimen; non-responder imputation for missing values). Clinical Stage EASI-90 NOTE: For illustrative purposes only. Efficacy data are derived from different clinical trials conducted at different times, with differences in trial design and patient populations. As a result, cross-trial comparisons cannot be made, and no head-to-head clinical trials have been conducted. Statistical treatment of missing data varies across studies shown. FDA Approved and Clinical Stage Biologics in AD

GRAPHIC

Filename: ea029706101_ex99-1img1.jpg · Sequence: 4

Binary file (14925 bytes)

Download ea029706101_ex99-1img1.jpg

GRAPHIC

Filename: ea029706101_ex99-2img1.jpg · Sequence: 5

Binary file (508579 bytes)

Download ea029706101_ex99-2img1.jpg

GRAPHIC

Filename: ea029706101_ex99-2img2.jpg · Sequence: 6

Binary file (1050012 bytes)

Download ea029706101_ex99-2img2.jpg

GRAPHIC

Filename: ea029706101_ex99-2img3.jpg · Sequence: 7

Binary file (196017 bytes)

Download ea029706101_ex99-2img3.jpg

GRAPHIC

Filename: ea029706101_ex99-2img4.jpg · Sequence: 8

Binary file (467192 bytes)

Download ea029706101_ex99-2img4.jpg

GRAPHIC

Filename: ea029706101_ex99-2img5.jpg · Sequence: 9

Binary file (441637 bytes)

Download ea029706101_ex99-2img5.jpg

GRAPHIC

Filename: ea029706101_ex99-2img6.jpg · Sequence: 10

Binary file (433540 bytes)

Download ea029706101_ex99-2img6.jpg

GRAPHIC

Filename: ea029706101_ex99-2img7.jpg · Sequence: 11

Binary file (413898 bytes)

Download ea029706101_ex99-2img7.jpg

GRAPHIC

Filename: ea029706101_ex99-2img8.jpg · Sequence: 12

Binary file (646036 bytes)

Download ea029706101_ex99-2img8.jpg

GRAPHIC

Filename: ea029706101_ex99-2img9.jpg · Sequence: 13

Binary file (475188 bytes)

Download ea029706101_ex99-2img9.jpg

GRAPHIC

Filename: ea029706101_ex99-2img10.jpg · Sequence: 14

Binary file (479132 bytes)

Download ea029706101_ex99-2img10.jpg

GRAPHIC

Filename: ea029706101_ex99-2img11.jpg · Sequence: 15

Binary file (400707 bytes)

Download ea029706101_ex99-2img11.jpg

GRAPHIC

Filename: ea029706101_ex99-2img12.jpg · Sequence: 16

Binary file (437952 bytes)

Download ea029706101_ex99-2img12.jpg

GRAPHIC

Filename: ea029706101_ex99-2img13.jpg · Sequence: 17

Binary file (200404 bytes)

Download ea029706101_ex99-2img13.jpg

GRAPHIC

Filename: ea029706101_ex99-2img14.jpg · Sequence: 18

Binary file (435634 bytes)

Download ea029706101_ex99-2img14.jpg

GRAPHIC

Filename: ea029706101_ex99-2img15.jpg · Sequence: 19

Binary file (316734 bytes)

Download ea029706101_ex99-2img15.jpg

GRAPHIC

Filename: ea029706101_ex99-2img16.jpg · Sequence: 20

Binary file (249072 bytes)

Download ea029706101_ex99-2img16.jpg

GRAPHIC

Filename: ea029706101_ex99-2img17.jpg · Sequence: 21

Binary file (463975 bytes)

Download ea029706101_ex99-2img17.jpg

GRAPHIC

Filename: ea029706101_ex99-2img18.jpg · Sequence: 22

Binary file (451904 bytes)

Download ea029706101_ex99-2img18.jpg

GRAPHIC

Filename: ea029706101_ex99-2img19.jpg · Sequence: 23

Binary file (180874 bytes)

Download ea029706101_ex99-2img19.jpg

GRAPHIC

Filename: ea029706101_ex99-2img20.jpg · Sequence: 24

Binary file (356036 bytes)

Download ea029706101_ex99-2img20.jpg

GRAPHIC

Filename: ea029706101_ex99-2img21.jpg · Sequence: 25

Binary file (330897 bytes)

Download ea029706101_ex99-2img21.jpg

GRAPHIC

Filename: ea029706101_ex99-2img22.jpg · Sequence: 26

Binary file (263690 bytes)

Download ea029706101_ex99-2img22.jpg

GRAPHIC

Filename: ea029706101_ex99-2img23.jpg · Sequence: 27

Binary file (349563 bytes)

Download ea029706101_ex99-2img23.jpg

GRAPHIC

Filename: ea029706101_ex99-2img24.jpg · Sequence: 28

Binary file (326161 bytes)

Download ea029706101_ex99-2img24.jpg

GRAPHIC

Filename: ea029706101_ex99-2img25.jpg · Sequence: 29

Binary file (325103 bytes)

Download ea029706101_ex99-2img25.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 34

v3.26.1

Cover

Jul. 07, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jul. 07, 2026

Entity File Number

001-42875

Entity Registrant Name

TURN THERAPEUTICS INC.

Entity Central Index Key

0002023016

Entity Tax Identification Number

32-0456090

Entity Incorporation, State or Country Code

Entity Address, Address Line One

250 N. Westlake Blvd.

Entity Address, City or Town

Westlake Village

Entity Address, State or Province

Entity Address, Postal Zip Code

91362

City Area Code

818

Local Phone Number

564-4011

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value $0.0001 per share

Trading Symbol

TTRX

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration